APLI:CC News and Press, Appili Therapeutics Inc.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug...

  US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOB...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on ...

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV‑01, which was developed using a proprietary TLI vaccine ...

New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth HALIFAX, Nova Scotia, Nov. ...

Los Angeles, California, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV‑01, which was developed using a proprietary TLI vaccine t...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company ...

HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium on Nove...

A look at the top 10 most actives in Canada Guanajuato Silver Company Ltd. (GSVR) fell 14.8% to $0.46 on volume of 8,580,513 shares Prospector Metals Corp. (PPP) rose 162.3% to $0.8 on volume of 4,005,473 shares National Bank of Canada (NA) rose 0.9% to $149.23 on volume of 3,600,714 shares...

Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government funding proposals HALIFAX, Nova Scotia, Oct. 01, 2025 (GLOBE NEWSWIRE...